Shares in Verve Therapeutics (NASDAQ: VERV) soared 80.5% this week on the news of an agreement for Eli Lilly (NYSE: LLY) to ...

A dramatic pullback in public biotech investment catalyzed by economic and regulatory upheaval is putting even more stress on ...

Drinking a cup or two of coffee every day may help you live longer -- but only if you skip the heavy cream and sugar, new ...

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

Eli Lilly just dropped $1 billion—plus a $300 million bonus if trials go well—on gene therapy firm Verve, aiming to spice up ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Key Takeaways Eli Lilly will acquire Verve for roughly $1 billionVerve is developing a one-time gene-editing treatment for ...

Global shares are mostly higher and oil prices have slipped as investors await a decision on interest rates by the Federal Reserve. The inflation-fighters at the Fed are expected to ...

Lilly’s Verve Therapeutics bid is a boon; CDC COVID-19 official resigns in protest of RFK Jr.; Former ACIP members rebuke RFK Jr. in joint essay.

Boston-based Verve is a rare example of a gene-editing company targeting a disease that affects a large population, offering ...